Share

|

eAlerts

|

Register

|

Login
Showcase

>

  • Showcases
  • >
  • Olaparib plus abiraterone could be a new first-line treatment option for mCRPC
Man in consultation
  • Oncology
  • Conference Coverage & Reporting

Olaparib plus abiraterone could be a new first-line treatment option for mCRPC

 

Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps (3:41).

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
Register Now

Showcase

JAK inhibitor safety image

JAK inhibitor safety: Distilling the evidence

MEET THE SENIOR TEAM

Lucy Piper

medwireNews Bureau Chief

Related Showcases

|

view all

  • Neurology

Unrestricted oral feedings reported by caregivers and affected persons across severity of…

  • Conference Coverage & Reporting
  • Neurology

Feasibility of assisted 6-minute cycle test shown in non-ambulatory SMA patients

  • Conference Coverage & Reporting
  • Neurology

Nusinersen treatment may improve aerobic capacity in adult SMA patients

  • Conference Coverage & Reporting
  • Neurology

Treatment linked to continued stabilization of motor function in adults with SMA

  • Conference Coverage & Reporting
  • Neurology

Study identifies miRNAs upregulated in SMA

  • Conference Coverage & Reporting
  • Neurology

EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of…

  • Conference Coverage & Reporting

Building relationships through trusted content for healthcare professionals

GET STARTED
A global leader in medical content

© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.

Twitter Icon-social_rss
Social Share
Contact
eAlerts
Register
Login
Terms of Use
Privacy Policy
Cookie Policy